Kenji Morimoto

4.3k total citations
117 papers, 1.5k citations indexed

About

Kenji Morimoto is a scholar working on Endocrinology, Diabetes and Metabolism, Oncology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Kenji Morimoto has authored 117 papers receiving a total of 1.5k indexed citations (citations by other indexed papers that have themselves been cited), including 39 papers in Endocrinology, Diabetes and Metabolism, 31 papers in Oncology and 30 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Kenji Morimoto's work include Diet, Metabolism, and Disease (38 papers), Lung Cancer Treatments and Mutations (25 papers) and Lung Cancer Research Studies (16 papers). Kenji Morimoto is often cited by papers focused on Diet, Metabolism, and Disease (38 papers), Lung Cancer Treatments and Mutations (25 papers) and Lung Cancer Research Studies (16 papers). Kenji Morimoto collaborates with scholars based in Japan, United Kingdom and United States. Kenji Morimoto's co-authors include Ken Izumori, Goro Takata, Tom Granström, Akihide Yoshihara, Goro Takada, George W. J. Fleet, Keiko Uechi, Khim Leang, Sarah F. Jenkinson and Tadaaki Yamada and has published in prestigious journals such as SHILAP Revista de lepidopterología, Blood and PLoS ONE.

In The Last Decade

Kenji Morimoto

113 papers receiving 1.5k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Kenji Morimoto Japan 23 673 441 219 206 200 117 1.5k
Jie Gao China 24 120 0.2× 910 2.1× 109 0.5× 95 0.5× 251 1.3× 90 1.7k
Rahul Ray United States 23 181 0.3× 467 1.1× 44 0.2× 85 0.4× 130 0.7× 68 1.6k
E Hollande France 22 154 0.2× 662 1.5× 423 1.9× 37 0.2× 155 0.8× 85 1.6k
Miki Imanishi Japan 25 158 0.2× 1.2k 2.8× 61 0.3× 90 0.4× 89 0.4× 106 2.1k
Laure Eloy France 18 194 0.3× 281 0.6× 133 0.6× 275 1.3× 121 0.6× 32 1.1k
Tikva Vogel United States 20 213 0.3× 713 1.6× 208 0.9× 23 0.1× 156 0.8× 30 1.6k
Wenjuan Jiang China 22 131 0.2× 593 1.3× 45 0.2× 71 0.3× 105 0.5× 77 1.3k
Jörg Müller Germany 19 92 0.1× 526 1.2× 193 0.9× 86 0.4× 110 0.6× 31 1.4k
Thomas H. Fischer Germany 21 144 0.2× 593 1.3× 133 0.6× 83 0.4× 52 0.3× 46 1.4k
Renata Jaskula‐Sztul United States 27 194 0.3× 1.0k 2.4× 60 0.3× 87 0.4× 508 2.5× 67 1.9k

Countries citing papers authored by Kenji Morimoto

Since Specialization
Citations

This map shows the geographic impact of Kenji Morimoto's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kenji Morimoto with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kenji Morimoto more than expected).

Fields of papers citing papers by Kenji Morimoto

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Kenji Morimoto. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kenji Morimoto. The network helps show where Kenji Morimoto may publish in the future.

Co-authorship network of co-authors of Kenji Morimoto

This figure shows the co-authorship network connecting the top 25 collaborators of Kenji Morimoto. A scholar is included among the top collaborators of Kenji Morimoto based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Kenji Morimoto. Kenji Morimoto is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Yamada, Tadaaki, Yuki Katayama, Ryo Sawada, et al.. (2024). Initial AXL and MCL‐1 inhibition contributes to abolishing lazertinib tolerance in EGFR‐mutant lung cancer cells. Cancer Science. 115(10). 3333–3345. 3 indexed citations
2.
Katayama, Yuki, Tadaaki Yamada, Kenji Morimoto, et al.. (2023). TTF-1 Expression and Clinical Outcomes of Combined Chemoimmunotherapy in Patients With Advanced Lung Adenocarcinoma: A Prospective Observational Study. JTO Clinical and Research Reports. 4(4). 100494–100494. 5 indexed citations
3.
4.
Kawachi, Hayato, Tadaaki Yamada, Akihiro Yoshimura, et al.. (2023). Rationale and design of phase II clinical trial of dual inhibition with ramucirumab and erlotinib in EGFR exon 19 deletion-positive treatment-naïve non-small cell lung cancer with high PD-L1 expression (SPIRAL-3D study). Therapeutic Advances in Medical Oncology. 15. 2621758–2621758. 1 indexed citations
5.
Takeda, Takayuki, Tadaaki Yamada, Keiko Tanimura, et al.. (2023). Age-Stratified Analysis of First-Line Chemoimmunotherapy for Extensive-Stage Small Cell Lung Cancer: Real-World Evidence from a Multicenter Retrospective Study. Cancers. 15(5). 1543–1543. 7 indexed citations
6.
Yamada, Tadaaki, Satomi Tanaka, Shinsuke Shiotsu, et al.. (2023). Comparison of the prognosis of symptomatic cerebral infarction and pulmonary embolism in patients with advanced non‐small cell lung cancer. Cancer Medicine. 12(8). 9097–9105. 4 indexed citations
7.
Yamada, Tadaaki, Yuki Katayama, Hayato Kawachi, et al.. (2023). Effects of Combined Therapeutic Targeting of AXL and ATR on Pleural Mesothelioma Cells. Molecular Cancer Therapeutics. 23(2). 212–222. 5 indexed citations
8.
Morimoto, Kenji, Tadaaki Yamada, Takayuki Takeda, et al.. (2023). Clinical Efficacy and Safety of First- or Second-Generation EGFR-TKIs after Osimertinib Resistance for EGFR Mutated Lung Cancer: A Prospective Exploratory Study. Targeted Oncology. 18(5). 657–665. 7 indexed citations
9.
Yamada, Tadaaki, Yasuhiro Gotô, Hiroshi Tanaka, et al.. (2023). A phase 2 trial of durvalumab treatment following radiation monotherapy in patients with non-small cell lung cancer ineligible for stage III chemoradiotherapy: The SPIRAL-RT study. European Journal of Cancer. 195. 113373–113373. 8 indexed citations
10.
11.
Katayama, Yuki, Tadaaki Yamada, Shinsaku Tokuda, et al.. (2022). Heterogeneity among tumors with acquired resistance to EGFR tyrosine kinase inhibitors harboring EGFR‐T790M mutation in non‐small cell lung cancer cells. Cancer Medicine. 11(4). 944–955. 5 indexed citations
12.
Morimoto, Kenji, Ryo Sawada, Tadaaki Yamada, et al.. (2022). A Real-World Analysis of Immune Checkpoint Inhibitor-Based Therapy After Osimertinib Treatment in Patients With EGFR-Mutant NSCLC. JTO Clinical and Research Reports. 3(9). 100388–100388. 5 indexed citations
13.
Matsui, Yohei, et al.. (2022). Efficacy and Safety of Paclitaxel/nab-paclitaxel Chemotherapy for Patients With Relapsed Small Cell Lung Cancer. Anticancer Research. 42(10). 4921–4928. 3 indexed citations
14.
Morimoto, Kenji, Junji Uchino, Takashi Yokoi, et al.. (2021). Impact of cancer cachexia on the therapeutic outcome of combined chemoimmunotherapy in patients with non-small cell lung cancer: a retrospective study. OncoImmunology. 10(1). 1950411–1950411. 33 indexed citations
15.
Yamada, Tadaaki, Kenji Morimoto, Akira Nakao, et al.. (2021). Impact of maintenance therapy following induction immunochemotherapy for untreated advanced non-small cell lung cancer patients. Journal of Cancer Research and Clinical Oncology. 148(11). 2985–2994. 1 indexed citations
16.
Tanimura, Keiko, Tadaaki Yamada, Mano Horinaka, et al.. (2021). Inhibition of c-Jun N-terminal kinase signaling increased apoptosis and prevented the emergence of ALK-TKI-tolerant cells in ALK-rearranged non-small cell lung cancer. Cancer Letters. 522. 119–128. 12 indexed citations
17.
Morimoto, Kenji, Tadaaki Yamada, Yuki Katayama, et al.. (2020). Impact of preexisting antinuclear antibodies on combined immunotherapy and chemotherapy in advanced non-small cell lung cancer patients. Medical Oncology. 37(12). 111–111. 12 indexed citations
18.
Komasawa, Nobuyasu, et al.. (2014). [Gasserian ganglion block for trigeminal neuralgia under dexmedetomidine sedation].. PubMed. 63(8). 901–3. 1 indexed citations
19.
Morimoto, Kenji, et al.. (1989). Five cases of mucormycosis of maxillary sinus.. Practica Oto-Rhino-Laryngologica. 82(8). 1087–1094. 2 indexed citations
20.
Asakura, Kohji, et al.. (1985). Clinicopathological review of 36 parotid tumors.. Practica Oto-Rhino-Laryngologica. 78(2). 211–219. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Jie Gao Breakdown of academic impact, for papers by Rahul Ray Breakdown of academic impact, for papers by E Hollande Breakdown of academic impact, for papers by Miki Imanishi Breakdown of academic impact, for papers by Laure Eloy Breakdown of academic impact, for papers by Tikva Vogel Breakdown of academic impact, for papers by Wenjuan Jiang Breakdown of academic impact, for papers by Jörg Müller Breakdown of academic impact, for papers by Thomas H. Fischer Breakdown of academic impact, for papers by Renata Jaskula‐Sztul
Rankless by CCL
2026